Jointly provided by The Leukemia & Lymphoma Society, RMEI, LLC, and Postgraduate Institute for Medicine.
Funding provided by The Leukemia & Lymphoma Society.
Release date: March 25, 2016
Valid through: March 25, 2017
Specialty: Hematology, Oncology
This activity is primarily for researchers in hematology/oncology and for hematologists and oncologists who diagnose and treat patients with hematologic malignancies. The program is designed to provide the intended audience with cutting-edge research about newly approved and emerging molecularly targeted therapeutics in treating and improving outcomes of patients with hematologic malignancies.
This program consists of 5 continuing education activities.
Click the links below to review the activity launch pages containing full disclosure information.
Molecularly Targeted Therapy of Acute Myeloid Leukemia (AML) – Module 1 — A. Thomas Look, MD
Module 2 — Adolfo Ferrando, MD, PhD
Module 3 — Thomas J. Kipps, MD, PhD
Module 4 — Pier Paolo Pandolfi, MD, PhD
Module 5 — Constantine S. Mitsiades, MD, PhD